Figure 6: Schematic representation of mechanisms by which miR-192 mediates its anti-angiogenic function.
From: A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer
On the basis of findings described in the manuscript, TWIST1 downregulates miR-192 levels in cancer cells, leading to increased HOXB9 and EGR1 levels. These two transcription factors, in turn, lead to increased levels of multiple pro-angiogenic factors and increased tumour angiogenesis. Systemic delivery of miR-192 using DOPC nanoliposomes represents a potent means of blocking tumour angiogenesis and reducing tumour growth.
